San Francisco, December 19, 2022--Cothera Bioscience today announced that it has dosed the first patient with PC-002, a first-in-class deubiquitinase (DUB) inhibitor, in a global multi-center phase 2 clinical trial for the treatment of high-grade B-cell lymphoma with Myc rearrangement (NCT05263583). This is a single-arm, single-agent proof-of-concept trial designed to...
Cothera Acquires Exclusive Worldwide Rights to Zotiraciclib, a Novel Oral Multi-kinase Inhibitor from Adastra Pharmaceuticals
Beijing, San Francisco, September 7, 2021--Cothera Bioscience today announced that it has reached an agreement to acquire exclusive worldwide rights to zotiraciclib (ZTR/TG02) from Adastra Pharmaceuticals, Inc.Dr. Alex Wu, Co-founder and CEO of Cothera Bioscience, said: "This is a very important strategic deal for Cothera as it broadens our pipeline...
Cothera Receives Authorization from the FDA to Conduct a Phase 2 Clinical Trial to Test Its Targeted MYC Mutation Inhibitor PC-002 for the Treatment of High-Grade B-cell Lymphoma
Beijing, San Francisco, June 17, 2021--Cothera Bioscience today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a global multi-center phase 2 clinical trial for the treatment of high-grade B-cell lymphoma that is resistant or refractory to first-line and second-line treatments with PC-002,...